Karyopharm Therapeutics Inc.
KPTI
$1.62
-$0.08-4.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 146.62M | 151.12M | 146.07M | 142.53M | 137.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 146.62M | 151.12M | 146.07M | 142.53M | 137.27M |
| Cost of Revenue | 126.99M | 130.79M | 131.57M | 137.05M | 141.83M |
| Gross Profit | 19.63M | 20.33M | 14.50M | 5.48M | -4.56M |
| SG&A Expenses | 101.98M | 104.54M | 105.21M | 109.63M | 110.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 228.97M | 235.33M | 236.77M | 246.67M | 252.48M |
| Operating Income | -82.35M | -84.21M | -90.71M | -104.14M | -115.21M |
| Income Before Tax | -224.77M | -194.96M | -196.00M | -124.62M | -123.57M |
| Income Tax Expenses | -32.00K | 8.00K | 43.00K | 1.00K | -5.00K |
| Earnings from Continuing Operations | -224.74 | -194.97 | -196.04 | -124.62 | -123.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -224.74M | -194.97M | -196.04M | -124.62M | -123.57M |
| EBIT | -82.35M | -84.21M | -90.71M | -104.14M | -115.21M |
| EBITDA | -82.19M | -83.98M | -90.41M | -103.79M | -114.89M |
| EPS Basic | -12.86 | -14.87 | -16.62 | -14.58 | -14.61 |
| Normalized Basic EPS | -5.86 | -7.11 | -8.21 | -9.11 | -9.13 |
| EPS Diluted | -13.09 | -15.09 | -16.62 | -14.58 | -14.61 |
| Normalized Diluted EPS | -5.79 | -7.04 | -8.21 | -9.11 | -9.13 |
| Average Basic Shares Outstanding | 77.53M | 57.21M | 43.66M | 34.15M | 33.82M |
| Average Diluted Shares Outstanding | 80.23M | 59.91M | 43.66M | 34.15M | 33.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |